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Abstract
Randomized controlled trials are considered the gold standard for evaluating social work interventions. However, published
reports can systematically overestimate intervention effects when researchers selectively report large and significant findings.
Publication bias and other types of reporting biases can be minimized through prospective trial registration that is now an
accepted part of medical research. In this article, we explain how trial registration can promote ethical and valid trials in social
work, and we explain how social work researchers can register trials. We conclude that journal editors should ask authors to
report trial registration numbers in all reports of randomized trials in social work.
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Introduction
Randomized controlled trials in social work are increasingly
common (Montgomery & Mayo-Wilson, 2009). They allow
researchers to estimate what would have happened if partici-
pants had not received an intervention, thus providing evidence
of the intervention’s effects. Because trial results can vary for
many reasons, including chance, comprehensive syntheses of
many trials (i.e., systematic reviews) provide the best overall
evidence of true effectiveness.
Well-conducted trials and reviews are considered the gold
standards in primary and secondary research (Schulz, 1996),
but both can be vulnerable to bias. For example, trials may
account for missing data in their analyses because participants
who do not return outcome measures differ from participants
who complete trials, that is, attrition bias. For systematic
reviews, missing trial data have the same effect as missing par-
ticipant data, and recent studies show that reporting bias may
be the most important source of bias in intervention science
today. Fortunately, reporting bias can be minimized through
a simple process, that is, trial registration.
Reporting Bias
Systematic reviews minimize bias by including all eligible
trials, including unpublished literature. This reduces the impact
of publication bias, which occurs when studies with large,
positive results are more likely to be published than studies
with small, nonsignificant results (Dickersin, 1997). Contacting
authors further reduces selective outcome reporting, which occurs
when trials are partially published; that is, certain outcomes
are chosen for publication based on their results (Hutton &
Williamson, 2000).
Publication bias and selective outcome reporting can occur
when researchers do not intend to mislead. For example,
researchers may believe that negative results are uninteresting,
and they may believe that positive outcomes are more impor-
tant than null results. For social work as a whole, however, the
effects of these reporting biases are analogous to conducting
trials in which outcomes are reported only for people who
improve.
Overestimating the effects of health and social interventions
can have serious consequences. For example, a review compar-
ing published and unpublished studies of antidepressants for
children demonstrated that published trials favor medication,
but unpublished data suggest that risks outweigh benefits
(Whittington et al., 2004). Consequently, the United States now
warns that children taking antidepressants might experience
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increased suicidal ideation (U.S. Food and Drug Administra-
tion [FDA], 2004), and the United Kingdom now recommends
that antidepressants not be used routinely for children (National
Institute for Health and Clinical Excellence, 2005).
Failing to publish entire trials is the most obvious type of
publication bias, but research also demonstrates subtle biases
contribute to inaccurate beliefs about intervention effects. Pos-
itive trials are more likely to be published quickly (Ioannidis,
1998), repeatedly (Tramer, Reynolds, Moore, & McQuay,
1997), in English (Egger et al., 1997), and in high-impact jour-
nals (Easterbrook, Gopalan, Berlin, & Matthews, 1991).
Additionally, incomplete reporting of trials may have the
same effect as other types of publication bias. Trials often mea-
sure outcomes at several time points with several instruments,
and researchers often conduct multiple analyses. Because
researchers select large and significant results for publication,
the published record systematically overestimates intervention
effects (Chan, Hrobjartsson, Haahr, Gotzsche, & Altman, 2004;
Counsell, Clarke, Slattery, & Sandercock, 1994). For example,
a study of the antidepressant paroxetine reported that it was
effective in reducing depression with minimal adverse effects
(Keller et al., 2001). Complete results retrieved through litiga-
tion (Kesselheim &Avorn, 2007) showed no significant benefit
over placebo for any of the eight prespecified outcomes, and
people receiving the drug experienced more adverse events
such as self-harm (Beecham & SmithKline, 1998). By includ-
ing only 15% of outcomes measured, the published report mis-
led readers about the true results of the study (Jureidini,
McHenry, & Mansfield, 2008).
The Importance of Negative Results
Today, a few dozen pharmaceutical manufacturers conduct or
sponsor the majority of drug trials. Almost all trials of a new
medication will be conducted by the developer and patent
holder, so researchers know where to look for information
about these trials. To obtain marketing authorization for new
products, companies are required to submit confidential data
and prespecified analytic plans to regulators, which can often
be obtained by researchers. These circumstances make it possi-
ble to identify and to compare trial protocols with published
reports, thus providing researchers with a tool to detect publi-
cation bias in drug research.
By comparison, numerous independent researchers conduct
social work research, and many groups study similar interven-
tions. Except for the purpose of ethical approval, social work
researchers may never submit their plans for external review.
Identifying all the studies that have evaluated a particular inter-
vention can be extremely challenging. For these reasons, it is
almost impossible to evaluate the true prevalence of reporting
bias in social work at this time.
Selective publication—known also as the ‘‘file drawer prob-
lem’’ (Rosenthal, 1979)—has been acknowledged for decades,
and empirical evidence still shows it is a current problem in
various fields (Dwan et al., 2008; Dwan, Gamble, Williamson,
& Kirkham, 2013). Despite their importance, negative results
are still undervalued by journals that preferentially publish sta-
tistically significant results. Several examples in social work
research highlight how the publication of negative effects can
be just as important as the publication of positive results. For
example, the Cambridge-Somerville Youth Study, completed
in 1945, was a randomized controlled trial of a social work
intervention for at-risk boys (Powers & Witmer, 1951). As
adults, men who received the intervention as boys said that it
helped them lead better lives (McCord, 1978). However, com-
parisons between treatment and control groups indicated that
they were more likely to have been convicted of a crime, to
abuse alcohol, to have a severe mental illness, and to die early
(McCord, 1978). Furthermore, men who received more of the
intervention were more likely to have adverse outcomes
(McCord, 1978). Publication of these negative results, and
additional research to understand them, likely prevented further
harm to vulnerable children.
The ‘‘file drawer problem’’ (Rosenthal, 1979) also reduces
the power of meta-analysis to identify positive or negative
effects. A review of Scared Straight by Petrosino, Turpin-
Petrosino, and Buehler (2002) demonstrates how valuable such
results are for secondary research. ‘‘Scared Straight’’ is a juve-
nile awareness program that aims to reduce reoffending by giv-
ing at-risk youth a firsthand experience of prison. However,
when Petrosino and colleagues (2002) conducted a systematic
review of Scared Straight, they found nine trials that collec-
tively showed the intervention increases reoffending. Most
studies did not report statistically significant results, so a
meta-analysis of several small studies was essential to resolve
the uncertainty about the program’s effects. If negative or non-
confirmatory results continue to be filed away without publica-
tion, harmful intervention programs will continue to be rolled
out unintentionally.
The Development of Trial Registration
The harmful effects of some interventions are primarily known
because researchers have published unexpected negative
results. Due to lack of publication or underreporting, harmful
effects of other interventions have certainly been missed.
Furthermore, many ineffective interventions appear to be effec-
tive based on published reports that do not contain the full
results.
Fortunately, reporting bias can be reduced. If investigators
would record the design of all trials before beginning recruit-
ment, researchers and practitioners could find all trials that
have been conducted using a permanent and publicly accessible
database (Simes, 1986). The FDA Modernization Act (U.S.
Congress, 1997) aimed to establish such a database with the
launch of ClinicalTrials.gov in 2000. To encourage registra-
tion, the International Committee of Medical Journal Editors
required that trials had to be prospectively registered to be con-
sidered for publication (De Angelis et al., 2005), requiring
information about 20 items (Table 1). Trials can be registered
on several databases; of these, ClinicalTrials.gov is the largest
with approximately 143,000 study records from 183 countries.
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Prospective trial registration quickly became an accepted
part of biomedical and public health research. For example, the
Consolidated Standards of Reporting Trials (CONSORT)
Statement is an evidence-based guideline for reporting trials;
it is the international standard for reporting trials in medicine,
and it is endorsed by over 600 journals and editorial groups. In
2010, CONSORT emphasized the importance of trial registra-
tion by adding ‘‘Trial registration number and name of trial reg-
istry’’ as a required item for all clinical trials (Schulz, Altman,
& Moher, 2010). Reports of social and psychological interven-
tions continue to omit information that is essential to under-
stand their conduct and results (Grant, Mayo-Wilson,
Melendez-Torres, & Montgomery, 2013), so leading journals
in social work, including Research on Social Work Practice,
are currently developing a CONSORT guideline for social and
psychological interventions (Grant, Mayo-Wilson, Hopewell,
et al., 2013; Montgomery et al., 2013). Following the extension
of such guidelines to social work, prospective registration may
soon be expected as well.
Registering a Trial
Registering a trial may take no more than 20 min (Zarin &
Keselman, 2007) and should occur after ethical approval has
been obtained but before recruitment begins. Registration
through ClinicalTrials.gov is done through a Web-based proto-
col registration system, which begins with a ‘‘quick start
guide’’ that leads the user through each stage of trial registra-
tion (Table 2). The system asks users to enter key details
including the study eligibility criteria, a description of the
intervention and comparator, target sample size, dates of
recruitment and completion, and the primary and secondary
outcome measures. Each trial is assigned a unique number that
can be included and linked to future reports, and each record is
made public following review by quality assurance personnel.
Users can update records as trials progress by adding results of
the trial, citations to publications, or changes to the protocol.
These changes are publicly archived to form a complete record
of the trial’s progress from design to implementation.
The time required to register a trial is minimal, and the ben-
efits of registration are multiple. By registering trials, researchers
increase the visibility of their work, and they can demonstrate
that they have followed best practices for conducting and report-
ing trials. Practitioners can use trial registries to identify the
best current evidence to help service users, and systematic
reviewers can utilize registries to identify published, unpub-
lished, and ongoing trials. Funding bodies can use trial regis-
tries to assess research activity and ensure effective allocation
of funds. Broadly, transparent and open reporting encourages
public confidence in research and practice.
In addition to the practical benefits, trial registration fulfills
ethical obligations between researchers and research partici-
pants (Zarin & Keselman, 2007). Participants in trials risk the
consequences of untested interventions and delays in treatment
in order to generate evidence that will help people with similar
problems; reporting trials accurately and completely is required
to fulfill the agreement that researchers make with people who
participate in research.
Conclusion
In addition to academic efforts to monitor and to promote trial
registration, public campaigns are currently encouraging govern-
ments, regulators, and research bodies to implement measures
necessary for the registration of all past, present, and future trials
(Goldacre, Heneghan, Godlee, & Chalmers, 2013). Fewer than
half of published trials may be adequately registered today
(Mathieu, Boutron, Moher, Altman, & Ravaud, 2009), but pro-
spective registration is quickly becoming a normal part of all
research involving human participants.
To conduct ethical and valid trials, social work researchers
can easily register all randomized trials before recruiting par-
ticipants. To promote best practices, journal editors could
Table 2. How to Register a Clinical Trial.
Steps for Registering a Clinical Study on clinicaltrials.gov
1. Log in to protocol registration system (PRS)
2. Enter the required and optional data (for help, use the ‘‘Quick Start
Guide’’)
3. After entering data, preview and check for accuracy
4. Submit the record
5. The record will appear in 2–5 business days
6. Modify and add results using the record identification number
Note. For more information, http://prsinfo.ClinicalTrials.gov or e-mail
register@ClinicalTrials.gov.
Table 1. Minimal Registration Data Set.
WHO Trial Registration Data Set
1. Unique trial number
2. Trial registration data
3. Secondary IDS
4. The funding source(s)
5. Primary sponsor
6. Secondary sponsor(s)
7. Responsible contact person
8. Research contact person
9. The title of the study
10. The official scientific title of the study
11. Research ethics review information
12. Condition being studied
13. Intervention(s)
14. Key inclusion and exclusion criteria of participants
15. Study type
16. Anticipated trial start date
17. Target sample size
18. Recruitment status
19. Primary outcome (and intended time-points)
20. Key secondary outcomes
The data fields were specified at a meeting convened by the World Health
Organization (WHO) in April 2004.
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encourage or require authors to report trial registration numbers
in all reports of randomized trials.
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